Showing 71 - 80 of 81
Once treatment is found to be effective in clinical studies, attention often focuses on optimum or efficacious treatment delivery. In treatment duration-response studies, the optimum treatment delivery refers to the treatment length that optimises the mean response. In many studies, the...
Persistent link: https://www.econbiz.de/10005447015
Modelling human genetic variation is critical to understanding the genetic basis of complex disease. The Human Genome Project has discovered millions of binary DNA sequence variants, called single nucleotide polymorphisms, and millions more may exist. As coding for proteins takes place along...
Persistent link: https://www.econbiz.de/10005447062
Two-stage randomisation designs are useful in the evaluation of combination therapies where patients are initially randomised to an induction therapy and then, depending upon their response and consent, are randomised to a maintenance therapy. In this paper we derive the best regular...
Persistent link: https://www.econbiz.de/10005447070
We propose a method for comparing survival distributions when cause-of-failure information is missing for some individuals. We use multiple imputation to impute missing causes of failure, where the probability that a missing cause is that of interest may depend on auxiliary covariates, and...
Persistent link: https://www.econbiz.de/10005447075
Persistent link: https://www.econbiz.de/10005734085
Persistent link: https://www.econbiz.de/10010684021
A dynamic treatment regime is a list of sequential decision rules for assigning treatment based on a patient's history. Q- and A-learning are two main approaches for estimating the optimal regime, i.e., that yielding the most beneficial outcome in the patient population, using data from a...
Persistent link: https://www.econbiz.de/10010717597
Persistent link: https://www.econbiz.de/10011036150
Adaptive designs, which allow the sample size to be modified based on sequentially computed observed treatment differences, have been advocated recently for monitoring clinical trials. Although such methods have a great deal of appeal on the surface, we show that such methods are inefficient and...
Persistent link: https://www.econbiz.de/10005559348
We consider the problem of estimating the regression coefficients in a competing risks model, where the relationship between the cause-specific hazard for the cause of interest and covariates is described using linear transformation models and when cause of failure is missing at random for a...
Persistent link: https://www.econbiz.de/10005559370